News
-
Roche NimbleGen Announces New Pre-Capture Multiplexing For Target Enrichment Technology In Sequencing
10/12/2011
With the decreasing cost and increasing throughput of sequencing, researchers require a high-performance, cost-effective sample preparation pipeline for targeted sequencing.
-
New Partnership To Create Research And Commercial Manufacturing Hub At UC Davis In Sacramento
10/12/2011
UC Davis Health System, PETNET Solutions Inc., a wholly owned subsidiary of Siemens Medical Solutions USA, Inc., and Northern California PET Imaging Center (NCPIC) announced recently that they will partner to establish a facility on the university's Sacramento campus for research and training in radiochemistry and for the commercial production of radiopharmaceutical products used in positron emission tomography (PET) scans -- an imaging technique that provides molecular information important for diagnosing disease and conducting clinical research.
-
Drug Companies Must Report Clinical Trial Results, Even When They Won't Lead To A Product
10/1/2011
Drug companies sponsoring human trials of possible new medications have ethical responsibilities to study participants and to science to disclose the results of their clinical research -- even when product development is no longer being pursued, says a commentary co-authored by a leading UC Davis drug researcher published online today in Science Translational Medicine.
-
New Low Cost Microscope Stage Incubator
9/26/2011
Highly versatile, use the H501-EC with a single 35mm Petri dish, a glass slide or chambered 57mm cover glass.
-
Roche Starts Early Stage Clinical Trial In Down Syndrome
9/12/2011
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of its first Phase 1 clinical trial to investigate the safety and tolerability of a molecule designed to address the cognitive and behavioral deficits associated with Down syndrome.
-
AMRI Receives NIH Contract Award For The Development Of Pre-Clinical Drug Candidates To Treat Diseases Of The Nervous System
8/21/2011
AMRI recently announced it received a federal contract award from the National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS) to provide chemistry and other drug discovery technologies in support of NINDS’ Medicinal Chemistry for Neurotherapeutics Program (MCNP), part of the NIH Blueprint Neurotherapeutics Network.
-
NeuroSigma Responds To Substantial Interest Generated By NPR Story On Promising Epilepsy Clinical Trial
8/8/2011
NeuroSigma, Inc., a Los Angeles-based medical device company, today provided an update in response to substantial interest and inquiries generated by a National Public Radio (NPR) news story which aired July 27, 2011 on the use of non-invasive Trigeminal Nerve Stimulation (TNS) for the treatment of drug-resistant epilepsy.
-
The Lancet Publishes Clinical Trial Data That Demonstrate Statistically Significant And Dose-Dependent Expression Of Dystrophin In Duchenne Muscular Dystrophy Patients Treated With AVI BioPharma's Eteplirsen
8/1/2011
AVI BioPharma, Inc., (NASDAQ: AVII), a developer of RNA-based therapeutics, today announced that data published in The Lancet from a Phase 1b/2 study of eteplirsen, the Company's exon-skipping therapy for the treatment of Duchenne muscular dystrophy (DMD), demonstrate that the treatment was well tolerated and was shown to induce statistically significant and dose-dependent improvements in dystrophin expression in patients.
-
Adeona Plans To Commercialize wellZin™ To Reduce Symptoms Of The Common Cold
8/1/2011
Adeona Pharmaceuticals, Inc. announced today that it has acquired exclusive access to two sets of clinical data demonstrating, with statistical significance, the safety and efficacy of a particular oral zinc formulation in reducing the duration and severity of symptoms associated with the common cold.
-
Amarantus BioSciences Reports Positive Data In Parkinson's Program
7/27/2011
Amarantus BioSciences, Inc., a biotechnology company developing MANF, a first-in-class, disease-modifying therapeutic protein that addresses an underlying form of cell death known as apoptosis, announced positive results from a pre-clinical experiment demonstrating that MANF significantly reduces the behavioral deficits caused by the neurotoxin 6-OHDA in a standard animal model of Parkinson's disease.
This website uses cookies to ensure you get the best experience on our website. Learn more